The newer anticoagulants are starting to settle in – finding their feet for treatment of deep vein thrombosis, then pulmonary embolism, then atrial fibrillation – can dabigatran prove its worth against warfarin when it comes to mechanical valves?
This article in September’s New England Journal of Medicine from Eikelboom and colleagues reports on a dose validation study, looking at around 250 patients who had either a recent (within seven days) valve replacement or one more than three months ago. The trial was stopped early, due to an excess of both strokes and excess bleeding in the dabigatran group.
Looks like warfarin still has a place – but the trials on the anti-Xa inhibitors are yet to come.
Read it here.
source | NEJM